-----Original Message-----
From: "Jeronimo Rafael Ruiz Leon"
Date: Tue, 17 Jun 2008 19:30:40 -0400
Subject: candidatos vacunales contra la influencia aviar

Estimados compañeros de la Red de Desastres:
Esta información sobre los candidatos vacunales contra la influencia aviar aparecida en la revista SEL-SEL del Instituto Finlay me parece interesante.
Saludos
Jerónimo

Dr. Jerónimo Rafael Ruiz León Ph.D.
Facultad de Medicina Veterinaria
Universidad de Granma. Cuba

4. EE.UU. - LOS CANDIDATOS VACUNALES DE ADN CONTRA LA INFLUENZA AVIAR H5N1, DESARROLLADOS POR VICAL INCORPORATED Y FORMULADOS CON EL ADYUVANTE PATENTADO POR ESTA COMPAÑÍA (VASXFECTIN®) HAN PROPORCIONADO UNA PROTECCIÓN COMPLETA EN ESTUDIOS PRECLÍNICOS CON RATONES Y HURONES (FERRETS) - LOS RESULTADOS FUERON PUBLICADOS EN EL NÚMERO DEL 15 DE JUNIO DE LA REVISTA JOURNAL OF INFECTIOUS DISEASES...

Vical Pandemic
Influenza Vaccines Provide Complete Protection in Animal Studies; The Journal of Infectious Diseases Publishes H5N1 Challenge Data... By Vical Incorporated... Vical Incorporated (Nasdaq: VICL) announced today the publication of results demonstrating that pandemic influenza DNA vaccines formulated with the company's patented Vaxfectin(R) adjuvant provided complete protection of mice and ferrets against lethal challenge with a highly pathogenic strain of H5N1 influenza virus. The publication of the data in the June 15 issue of The Journal of Infectious Diseases (JID)(1) expands previously reported results supporting human clinical testing of the vaccine candidates. "We believe DNA vaccines offer significant advantages over conventional approaches," said Vijay B. Samant, Vical's President and Chief Executive Officer. "The publication of our pandemic influenza vaccine animal challenge data in a peer-reviewed scientific journal illustrates the approaches we are currently pursuing in our Phase 1 trial, and we look forward to releasing initial results from this study by August. This trial is also important because it marks the first time in humans for our Vaxfectin(R) adjuvant, which has potential applications with both DNA vaccines and conventional protein- based vaccines." DNA vaccines can be adapted quickly to target emerging strains of influenza, manufactured in a few weeks in generic fermentation equipment, and stored for extended periods of time.
Vical Pandemic Influenza Vaccines Provide Complete Protection in ... SunHerald.com - The publication of the data in the June 15 issue of The Journal of Infectious Diseases (JID)(1) expands previously reported results supporting human clinical testing of the vaccine candidates. "We believe DNA vaccines offer significant advantages over... Vical Pandemic Influenza Vaccines Provide Complete Protection in ... Lifescience- online - The publication of the data in the June 15 issue of The Journal of Infectious Diseases (JID)(1) expands previously reported results supporting human clinical testing of the vaccine candidates. "We believe DNA vaccines offer significant advantages over...